Phase 3 Dupixent Study Marks a Breakthrough for People with CSU
A new phase 3 study of Dupixent (dupilumab) reports strong results for chronic spontaneous urticaria (CSU). Patients who had a hard time with standard care saw meaningful relief, with clear improvements in both itch and hives.
Clear Gains in Patient Outcomes
Building on findings from CUPID-A, the LIBERTY-CUPID Study C showed that biologic-naive patients on Dupixent had nearly a 50% drop in itch and a marked decrease in overall urticaria activity compared with placebo. The trial enrolled 151 participants—children and adults—underscoring Dupixent’s potential to help a broad range of people living with CSU.
Key Study Findings
At 24 weeks, patients receiving Dupixent reported an 8.64-point reduction in itch severity, versus a 6.10-point reduction with placebo. Dupixent also outperformed placebo on urticaria activity scores, with a 15.86-point decrease compared with 11.21 points for placebo. Notably, 30% of patients on Dupixent had a complete resolution of urticaria symptoms, compared with 18% among those on placebo.
Why This Matters for Daily Life
CSU can be relentless—itch and hives that flare without warning and get in the way of sleep, school, work, and everything in between. Commenting on the results, Dr. Dietmar Berger of Sanofi emphasized that Dupixent could offer a much-needed option for people who don’t get enough relief from antihistamines.
Safety Profile and Next Steps
Safety results were in line with Dupixent’s established profile. Treatment-emergent adverse events occurred at similar rates in the Dupixent and placebo groups, reinforcing the medicine’s known safety. The study data will be submitted to the US Food and Drug Administration (FDA) to support Dupixent’s application for use in CSU.
Understanding Chronic Spontaneous Urticaria (CSU)
CSU is defined by recurring hives that appear without a clear trigger. In many cases, type-2 inflammation plays a role. First-line treatments like H1 antihistamines often aren’t enough, leaving many patients with persistent symptoms. In that context, Dupixent could become an important addition to care, offering another path to relief.
What’s Ahead for Dupixent in CSU
Dupixent is already approved for several conditions in more than 60 countries, with over one million patients treated so far. These new CSU results add to that track record and may open the door for more people to gain better control over a difficult, chronic condition.
Frequently Asked Questions
What is Dupixent?
Dupixent (dupilumab) is a monoclonal antibody that blocks signaling of interleukin-4 and interleukin-13, key drivers of type-2 inflammation. By targeting these pathways, it offers a treatment option for chronic inflammatory conditions, including CSU under study.
What are the standout results from this study?
Patients on Dupixent saw nearly a 50% reduction in itch and greater drops in urticaria activity than placebo. At 24 weeks, itch severity fell by 8.64 points with Dupixent versus 6.10 with placebo, and urticaria activity fell by 15.86 points versus 11.21 with placebo.
How many people took part, and who were they?
The trial enrolled 151 biologic-naive participants, including both children and adults. This mix helps show how the treatment performed across age groups.
What do these findings mean for people who don’t respond to antihistamines?
The results suggest Dupixent could be a valuable option for those whose CSU remains uncontrolled on standard H1 antihistamines, with meaningful improvements in itch, hive activity, and, for some, complete symptom resolution.
How did Dupixent’s safety compare with placebo?
Safety was consistent with Dupixent’s established profile, and treatment-emergent adverse events occurred at similar rates in both groups. The study data will be submitted to the FDA to support a potential CSU indication.
